Skip to main content

Poolbeg Pharma sees "significant commercial opportunity" in oral vaccines

Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) CEO Jeremy Skillington speaks to Thomas Warner from Proactive after announcing that work on the company's Oral Vaccine Programme collaboration is now set to move into a new phase. Taking place over three years, the EncOVac Consortium is funded to develop a Phase I clinical trial ready oral vaccine candidate. Skillington says "as technologies develop, we move away from injectables so we see great significant commercial opportunities in having an oral alternative." The focus of the next phase is to commence the validation of the encapsulation process.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.